RxDoctor Payments Data

Elton Shapiro, MD

Endocrinology, Diabetes & Metabolism · Aventura, FLNPI 1275551442

Payments from drug & device makers

$45,158in general payments, 2019–2025

Across 66 payments — averaging $684.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$37K
  • Merck$5K
  • Tosoh Bioscience, Inc.$2K
  • Tandem Diabetes Care, Inc.$168
  • Sanofi-aventis U.S. LLC$120
  • Sanofi$110
  • plus $224 from 6 others

What the payments were for

  • Speaking & faculty fees$40,19989%
  • Travel & lodging$1,3203%
  • Food & beverage$1,2853%
  • Education$10%
  • Gifts$2,3535%

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,158 in reported general payments places this provider in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$218,021
Medicare patients
556
Services billed
4,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide221$334,062
TrulicityDulaglutide133$179,572
OzempicSemaglutide111$130,729
FarxigaDapagliflozin Propanediol150$130,197
JardianceEmpagliflozin89$94,614
Tresiba Flextouch U-100Insulin Degludec122$64,120
JanuviaSitagliptin Phosphate65$62,559
TradjentaLinagliptin44$44,762
Tresiba Flextouch U-200Insulin Degludec43$43,947
SynthroidLevothyroxine Sodium220$21,775
Humalog Kwikpen U-100Insulin Lispro91$17,775
Novolog FlexpenInsulin Aspart93$16,237
Nano 2nd Gen Pen NeedlePen Needle, Diabetic166$15,478
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$15,330
Lantus SolostarInsulin Glargine,hum.Rec.Anlog173$14,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$24$513,634354 claims
Novo NordiskOzempic, Novolog$37,338$131,758122 claims
MerckJanuvia$4,846$62,55965 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →